EHA 2021 – Curis’s renaissance continues

In December, six patients’ worth of data boosted Curis’s stock more than fivefold. Yesterday, results in another three patients added 66% to the company’s market cap and raised hopes that the group could have a viable project in the oral Irak-4 inhibitor CA-4948.

But it is early days for the asset and Curis still has a lot to do. The data, detailed in a EHA abstract, come from a phase 1/2 study in patients with acute myelogenous leukaemia or myelodysplastic syndrome: in nine evaluable subjects, there were two complete responses and two bone marrow complete responses.